ImageneBio (IMA) Income from Continuing Operations (2020 - 2025)
ImageneBio (IMA) posted Income from Continuing Operations of 24753000.0 for Q3 2025, down 794.58% sequentially from 2767000.0 in Q2 2025, and down 677.66% YoY from 4285027.41 in Q3 2024.
ImageneBio (IMA) Income from Continuing Operations (2020 - 2025) Analysis & Trends
ImageneBio has reported Income from Continuing Operations for 6 years, with the latest figure at 24753000.0 in Q3 2025.
- Quarterly Income from Continuing Operations fell 677.66% year-over-year to 24753000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 51103000.0 (up 3.05% YoY) and the FY2024 annual result came in at 49234000.0, up 27.77% from the prior year.
- Income from Continuing Operations eased to 24753000.0 in Q3 2025 per IMA's latest filing, from 2767000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2767000.0 in Q2 2025 and troughed at 2143937000.0 in Q2 2022.
- A 5-year average of 191608315.79 and a median of 17478000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 3859.26% in 2022, then soared 99.2% in 2023.
- Over 5 years, Income from Continuing Operations stood at 30478000.0 in 2021, then surged by 47.96% to 15861000.0 in 2022, then retreated by 23.9% to 19651000.0 in 2023, then increased by 11.06% to 17478000.0 in 2024, then slumped by 41.62% to 24753000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 24753000.0, 2767000.0, and 6105000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.75 Mn |
| Jun 30, 2025 | -2.77 Mn |
| Mar 31, 2025 | -6.11 Mn |
| Dec 31, 2024 | -17.48 Mn |
| Sep 30, 2024 | -3.18 Mn |
| Jun 30, 2024 | -13.73 Mn |
| Mar 31, 2024 | -16.15 Mn |
| Dec 31, 2023 | -19.65 Mn |
| Sep 30, 2023 | -17.34 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -14.22 Mn |
| Dec 31, 2022 | -15.86 Mn |
| Sep 30, 2022 | -1.05 Bn |
| Jun 30, 2022 | -2.14 Bn |
| Mar 31, 2022 | -22.57 Mn |
| Dec 31, 2021 | -30.48 Mn |
| Sep 30, 2021 | -49.38 Mn |
| Jun 30, 2021 | -54.15 Mn |
| Mar 31, 2021 | -121.50 Mn |
| Dec 31, 2020 | -31.52 Mn |